UCB's Global Corporate Website
Welcome to UCB in the United States

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Mar

26

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Mar

25

UCB at the 2022 AAD Annual Meeting: Our Commitment to Advancing Science in Dermatology

 

 

Mar

24

North Carolina Academic Engagement Night - Investing in our Future through STEM

At UCB, we are committed to accelerating scientific discoveries by supporting innovation ultimately leading to the discovery of new solutions to help people capture the moments that matter. Part of this commitment is a strong foundational support for STEM education in our communities to help inspire the next generation of scientists.

Mar

15

Voices on Value: Building a Sustainable Healthcare System Together – Our U.S. Sustainable Access and Pricing Transparency Report

Last year, UCB launched its Voices on Value blog series to foster a dialogue around how to make our health system better, stronger, and more accessible now and in the future. To advance this dialogue, UCB is releasing its first-ever U.S. Sustainable Access and Pricing Transparency Report, which underscores UCB’s commitment to an innovative, competitive, and value-based system. 

Mar

07

UCB Completes Acquisition of Zogenix, Inc.